Literature DB >> 11285563

Evaluation of hepatitis C antibody testing in saliva specimens collected by two different systems in comparison with HCV antibody and HCV RNA in serum.

G J van Doornum1, A Lodder, M Buimer, E J van Ameijden, S Bruisten.   

Abstract

Two different ELISA assays, the Ortho HCV 3.0 ELISA (Ortho Diagnostics Systems) and the Mono-Lisa anti-HCV Plus (Sanofi Diagnostics Pasteur) were evaluated for the detection of hepatitis C virus (HCV) antibody in saliva samples. Specimens were collected from 152 individuals who participated in a longitudinal cohort study on HIV infection, and who used illicit drugs. Saliva specimens were collected using two different systems: Salivette (Sarstedt) and Omni-Sal (Saliva Diagnostic Systems). Saliva specimens were tested following modified protocols by both ELISAs, and the results were compared with serum specimens that were tested according to the instructions of the manufacturer. Serum samples of 102 (67%) participants were positive by both assays, and 50 persons were negative for HCV antibody. A total of 99 of the 102 serum specimens were confirmed as positive using Ortho Riba HCV 3.0 (Ortho Diagnostics System) and Deciscan HCV (Sanofi Diagnostics Pasteur), and 3 yielded discrepant results. As no cut-off level is known for testing saliva samples by ELISA, 3 different levels were chosen: mean (M) + 1 standard deviation (SD), M + 2 SD, and M + 3 SD of the optical densities of saliva tests of the 50 HCV serum antibody negative persons. At a level of M + 1 SD and M + 2 SD the Salivette/Mono-Lisa combination gave the greatest proportion of HCV antibody positive saliva specimens obtained from the 102 HCV serum antibody positive participants, 88% and 79%, respectively. Differences between the various collection systems and assay combinations were not significant statistically. In 76 of the 102 persons with HCV antibodies in serum, HCV RNA was detected in serum. Salivary presence of HCV RNA, however, could not be demonstrated. The results show that the assays compared are unsuitable for diagnostic use, but the sensitivities of the assays are acceptable for use in epidemiological studies. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11285563     DOI: 10.1002/jmv.1011

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  9 in total

1.  Illicit opioid use in Canada: comparing social, health, and drug use characteristics of untreated users in five cities (OPICAN study).

Authors:  Benedikt Fischer; Jürgen Rehm; Suzanne Brissette; Serge Brochu; Julie Bruneau; Nady El-Guebaly; Lina Noël; Mark Tyndall; Cameron Wild; Phil Mun; Dolly Baliunas
Journal:  J Urban Health       Date:  2005-05-04       Impact factor: 3.671

2.  Accuracy of rapid oral HCV diagnostic test among a Saudi sample.

Authors:  Suzan Ibrahim; Safia Ali Al Attas; Ghada Anwar Mansour; Soliman Ouda; Hind Fallatah
Journal:  Clin Oral Investig       Date:  2014-05-21       Impact factor: 3.573

3.  Recognition of multiple classes of hepatitis C antibodies increases detection sensitivity in oral fluid.

Authors:  J F Zmuda; B Wagoneer; L Liotta; G Whiteley
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

4.  Correlation between detection of antibodies against hepatitis C virus in oral fluid and hepatitis C virus RNA in serum.

Authors:  L Cock De; V Hutse; R Vranckx
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-08       Impact factor: 3.267

5.  Evaluation of saliva specimens as an alternative sampling method to detect hepatitis B surface antigen.

Authors:  Helena Medina Cruz; Elisangela Ferreira da Silva; Cristiane A Villela-Nogueira; Letícia C Nabuco; Kycia Maria Rodrigues do Ó; Lia Laura Lewis-Ximenez; Clara Fumiko Tachibana Yoshida; Elisabeth Lampe; Livia Melo Villar
Journal:  J Clin Lab Anal       Date:  2011       Impact factor: 2.352

6.  Detection of hepatitis C virus antibodies in oral fluid specimens for prevalence studies.

Authors:  V González; E Martró; C Folch; A Esteve; L Matas; A Montoliu; J R Grífols; F Bolao; C Tural; R Muga; J V Parry; V Ausina; J Casabona
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-11-20       Impact factor: 3.267

7.  Prevalence of HIV and hepatitis C virus infections among inmates of Ontario remand facilities.

Authors:  Liviana Calzavara; Nancy Ramuscak; Ann N Burchell; Carol Swantee; Ted Myers; Peter Ford; Margaret Fearon; Sue Raymond
Journal:  CMAJ       Date:  2007-07-31       Impact factor: 8.262

Review 8.  Salivary Exosomes as Nanocarriers for Cancer Biomarker Delivery.

Authors:  Jordan Cheng; Taichiro Nonaka; David T W Wong
Journal:  Materials (Basel)       Date:  2019-02-21       Impact factor: 3.748

Review 9.  Fighting viruses with materials science: Prospects for antivirus surfaces, drug delivery systems and artificial intelligence.

Authors:  Vinicius Rosa; Dean Ho; Robinson Sabino-Silva; Walter L Siqueira; Nikolaos Silikas
Journal:  Dent Mater       Date:  2021-01-10       Impact factor: 5.304

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.